These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 37689630

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study.
    Veit T, Barnikel M, Crispin A, Kneidinger N, Ceelen F, Arnold P, Munker D, Schmitzer M, Barton J, Schiopu S, Schiller HB, Frankenberger M, Milger K, Behr J, Neurohr C, Leuschner G.
    Respir Res; 2020 Oct 19; 21(1):270. PubMed ID: 33076914
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The natural history of progressive fibrosing interstitial lung diseases.
    Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, Goeldner RG, Clerisme-Beaty E, Tetzlaff K, Cottin V, Wells AU.
    Eur Respir J; 2020 Jun 19; 55(6):. PubMed ID: 32217654
    [Abstract] [Full Text] [Related]

  • 26. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO, TRAIL1 Network Investigators.
    Lancet Respir Med; 2023 Jan 19; 11(1):87-96. PubMed ID: 36075242
    [Abstract] [Full Text] [Related]

  • 27. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S.
    Mod Rheumatol; 2021 Jan 19; 31(1):13-19. PubMed ID: 32964766
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Lung function trajectory in progressive fibrosing interstitial lung disease.
    Oldham JM, Lee CT, Wu Z, Bowman WS, Pugashetti JV, Dao N, Tonkin J, Seede H, Echt G, Adegunsoye A, Chua F, Maher TM, Garcia CK, Strek ME, Newton CA, Molyneaux PL.
    Eur Respir J; 2022 Jun 19; 59(6):. PubMed ID: 34737223
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
    Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T.
    Respir Med; 2021 Oct 19; 187():106574. PubMed ID: 34564020
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.
    Yıldırım F, Türk M, Bitik B, Erbaş G, Köktürk N, Haznedaroğlu Ş, Türktaş H.
    Kaohsiung J Med Sci; 2019 Jun 19; 35(6):365-372. PubMed ID: 30913371
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease.
    Katano T, Sekine A, Ikeda S, Yamakawa H, Misumi T, Okabayashi H, Okuda R, Kitamura H, Baba T, Komatsu S, Hagiwara E, Ogura T.
    Respir Investig; 2021 Jul 19; 59(4):414-420. PubMed ID: 33618993
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline.
    Nagy A, Nagy T, Kolonics-Farkas AM, Eszes N, Vincze K, Barczi E, Tarnoki AD, Tarnoki DL, Nagy G, Kiss E, Maurovich-Horvat P, Bohacs A, Müller V.
    Front Pharmacol; 2021 Jul 19; 12():778649. PubMed ID: 35002713
    [Abstract] [Full Text] [Related]

  • 40. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.
    Maher TM, Bourdin A, Volkmann ER, Vettori S, Distler JHW, Alves M, Stock C, Distler O.
    Respir Res; 2022 Jul 05; 23(1):178. PubMed ID: 35790961
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.